GlobalData has released its new Country report, PharmaPoint:
Meningococcal Vaccines United States Drug Forecast and Market Analysis to 2022.
Meningococcal disease is an acute infection caused by the gram-negative
bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms
makes prompt and effective diagnosis and treatment nearly impossible. For these
reasons the meningococcal disease space is dominated by vaccines. Currently,
tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo,
account for the vast majority of global sales, with the US adolescent market
being the key target segment. GlobalData expects growth in the meningococcal
vaccines market to be primarily driven by the launch of serotype B vaccines,
which address a critical unmet need in the treatment landscape. Vaccines that
better protect infants and/or provide a longer duration of immunity also have
an opportunity to seize market share during 2012-2022.
To
Read The Complete Report with TOC : http://www.marketresearchreports.biz/analysis-details/pharmapoint-meningococcal-vaccines-united-states-drug-forecast-and-market-analysis-to-2022
GlobalData has released its new
Country report, PharmaPoint: Meningococcal Vaccines France Drug Forecast and
Market Analysis to 2022. Meningococcal disease is an acute infection caused by
the gram-negative bacterium Neisseria meningitidis. Its rapid onset and
severity of symptoms makes prompt and effective diagnosis and treatment nearly
impossible. For these reasons the meningococcal disease space is dominated by
vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra
and Novartis Menveo, account for the vast majority of global sales, with the US
adolescent market being the key target segment. GlobalData expects growth in
the meningococcal vaccines market to be primarily driven by the launch of
serotype B vaccines, which address a critical unmet need in the treatment
landscape. Vaccines that better protect infants and/or provide a longer
duration of immunity also have an opportunity to seize market share during
2012-2022.
To
Read The Complete Report with TOC : http://www.marketresearchreports.biz/analysis-details/pharmapoint-meningococcal-vaccines-france-drug-forecast-and-market-analysis-to-2022
GlobalData does not expect relative
patient share to change within the MenC conjugate space because Nuron Biotechs
Meningitec, Novartis Menjugate kit, and Baxters NeisVac-C all possess similar
clinical profiles and price points. The MenC conjugate patient share is largely
determined by prescriber preference in France and therefore is not expected to
change drastically during the forecast period. The French government has
expressed disappointment with the low coverage rates of its MenC immunization
program and is expected to renew efforts to expand vaccine use (Stahl et al.,
2013). In general, the sales potential in France is derived from the
immunization recommendations, which largely determine vaccine usage.
GlobalData has released its new
Country report, PharmaPoint: Meningococcal Vaccines Germany Drug Forecast and Market
Analysis to 2022. Meningococcal disease is an acute infection caused by the
gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of
symptoms makes prompt and effective diagnosis and treatment nearly impossible.
For these reasons the meningococcal disease space is dominated by vaccines.
Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and
Novartis Menveo, account for the vast majority of global sales, with the US
adolescent market being the key target segment. GlobalData expects growth in
the meningococcal vaccines market to be primarily driven by the launch of
serotype B vaccines, which address a critical unmet need in the treatment
landscape. Vaccines that better protect infants and/or provide a longer duration
of immunity also have an opportunity to seize market share during 2012-2022.
To
Read The Complete Report with TOC : http://www.marketresearchreports.biz/analysis-details/pharmapoint-meningococcal-vaccines-germany-drug-forecast-and-market-analysis-to-2022
GlobalData predicts that relative
patient share for the three MenC conjugate vaccines will remain unchanged for
the duration of the forecast period because Nuron Biotechs Meningitec, Novartis
Menjugate kit, and Baxters NeisVac-C possess nearly identical clinical profiles
and price points. The MenC conjugate patient share is largely determined by
prescriber preference in Germany and therefore is not expected to change
drastically during the forecast period.
Scope
- Overview of Meningococcal
Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology
and treatment guidelines as well as an overview on the competitive
landscape.
- Detailed information on the key
drugs in Germany including product description, safety and efficacy
profiles as well as a SWOT analysis.
- Sales forecast for the top
drugs in Germany from 2012-2022.
- Analysis of the impact of key
events as well the drivers and restraints affecting Germany Meningococcal
Vaccines market.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment